IP Library Granted Patent US 12,408,977
Granted Patent B2
US 12,408,977 · App. 18/173,000 · Granted Sep 9, 2025

Methods for monitoring ablation progress with doppler ultrasound

Inventor: Jiayu Chen (Palo Alto, CA)
Assignee: Gynesonics, Inc.
A61B18/1492A61B18/1477A61B90/37A61B2018/00577A61B2018/143A61B2090/378
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,408,977
App. No.
18/173,000
Granted
Sep 9, 2025
Kind
B2
Abstract

Systems and methods for treating tissue are disclosed. The target tissue is ablated. A real-time image of the target tissue is generated during the ablation. The real-time blood perfusion level of the target tissue is determined from the real-time image and compared to an initial blood perfusion level of the target tissue. The comparison provides a metric for the progress of the ablation, and ablation is halted when the real-time blood perfusion drops below a threshold level relative to the initial blood perfusion level.

Claims (28)

1. A system for treating a target tissue, the system comprising:

a treatment probe comprising a handle, a probe body, an imaging source coupled to the probe body, and an ablation element coupled to the probe body and configured to ablate the target tissue;

a real-time display coupled to the treatment probe; and

a controller coupled to the imaging source of the treatment probe and the real-time display, the controller comprising a computer readable, non-transient storage medium comprising:

(i) instructions for the imaging source to generate a real-time image of the target tissue during ablation of the target tissue,

(ii) instructions for the real-time display to display the real-time image, the real-time image showing the target tissue and a virtual treatment boundary around the target tissue,

(iii) instructions for determining an initial blood perfusion of the target tissue,

(iv) instructions for, prior to initiating ablation of the target tissue, modifying one or more of a size or location of the virtual treatment boundary based on the determined initial blood perfusion of the target tissue, and

(v) instructions for determining a real-time blood perfusion level within the virtual treatment boundary, and determining a completion percentage of the ablation of the target tissue within the virtual treatment boundary based on the determined real-time blood perfusion level within the virtual treatment boundary, thereby indicating to a user a progress of the ablation of the target tissue.

2. A system as in claim 1 , wherein the ablation element comprises a needle structure extendable from the treatment probe into the target tissue.

3. A system as in claim 2 , wherein the ablation element further comprises a plurality of needles extendable from the needle structure into the target tissue.

4. A system as in claim 1 , wherein the computer readable, non-transient storage medium further comprises instructions for the real-time display to display the real-time blood perfusion level on the real-time image.

5. A system as in claim 1 , wherein the computer readable, non-transient storage medium further comprises instructions for determining whether the determined real-time blood perfusion level within the virtual treatment boundary is below a threshold amount, and indicating to the user to halt ablation of the target tissue in response to the real-time blood perfusion level being below the threshold amount.

6. A system as in claim 5 , wherein the threshold amount is a percentage threshold amount, and wherein the computer readable, non-transient storage medium further comprises instructions for determining an initial blood perfusion level within the virtual treatment boundary, determining a percentage decrease of the determined real-time blood perfusion level within the virtual treatment boundary relative to the determined initial blood perfusion level within the virtual treatment boundary, and indicating to the user to halt ablation of the target tissue in response to the determined percentage decrease of the determined real-time blood perfusion level within the virtual treatment boundary being below the percentage threshold amount.

7. A system as in claim 6 , wherein the percentage threshold amount is 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the initial blood perfusion amount of the target tissue.

8. A system as in claim 6 1 , wherein determining the initial blood perfusion of the target tissue comprises determining Doppler ultrasound signals in the target tissue, and wherein determining the real-time blood perfusion level within the virtual target boundary comprises determining a level of Doppler ultrasound signals within the virtual target boundary.

9. A system as in claim 1 , wherein a position of the imaging source is configured to be fixed in relation to the target tissue during the ablation of the target tissue.

10. A system as in claim 9 , wherein the real-time image of the target tissue is generated during the ablation with the position of the imaging source fixed in relation to the target tissue.

11. A system as in claim 1 , wherein the imaging source is configured to be in a fixed position in relation to the ablation element.

12. A system as in claim 1 , wherein the imaging source is configured to be movable relative to the ablation element.

13. A system as in claim 1 , wherein the real-time image of the target tissue comprises at least one ultrasound image of the target tissue.

14. A system as in claim 13 , wherein the at least one ultrasound image comprises one or more of a contrast enhanced ultrasound image, a B-mode ultrasound image, or a Doppler ultrasound image.

15. A system as in claim 14 , wherein the at least one ultrasound image comprises a B-mode ultrasound image and a Doppler ultrasound image overlaid over one another.

16. A system as in claim 1 , wherein the target tissue comprises a fibroid, a uterine fibroid, a fibroid tissue, a tumor, a tissue hyperplasia, or an undesired scar tissue.

17. A system as in claim 1 , wherein the computer readable, non- transient storage medium further comprises instructions for the real-time display to superimpose the real-time virtual treatment boundary over the real-time image.

18. A system as in claim 1 , wherein the computer readable, non-transient storage medium further comprises instructions for the real-time display to display the determined completion percentage of the ablation of the target tissue within the virtual treatment boundary to the user.

19. A system as in claim 1 , wherein the computer readable, non-transient storage medium further comprises instructions for determining a real-time virtual ablation boundary based on a real-time blood perfusion in the target tissue, and alerting the user if the real-time virtual ablation boundary is outside of the virtual treatment boundary.

20. A system as in claim 1 , wherein the computer readable, non- transient storage medium further comprises instructions for modifying the one or more of the size or location of the virtual treatment boundary in response to user manipulation of one or more control elements.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 070236/0154 Recorded Apr 24, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: GYNESONICS, INC.
Reel/Frame 075455/0789 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Feb 14, 2025
From: GYNESONICS, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 070236/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2023
From: CHEN, JIAYU
To: GYNESONICS, INC.
Reel/Frame 062773/0684 →
Continuity (4)
Continuation 16666271 · Oct 28, 2019
Continuation PCTUS2018030295 · Apr 30, 2018
Provisional Application 62501238 · May 4, 2017
Related Publication 20240024023A1 · Jan 25, 2024
References Cited (93)
US 5979453A · Savage · 1999 [cited by examiner]
US 6315730B1 · Hoff · 2001 [cited by examiner]
US 6540677B1 · Angelsen et al. · 2003 [cited by applicant]
US 6575969B1 · Rittman, III · 2003 [cited by examiner]
US 6602251B2 · Burbank et al. · 2003 [cited by applicant]
US 6623481B1 · Garbagnati et al. · 2003 [cited by applicant]
US 6936048B2 · Hurst · 2005 [cited by applicant]
US 6944490B1 · Chow · 2005 [cited by applicant]
US 6969354B1 · Marian · 2005 [cited by applicant]
US 7160296B2 · Pearson et al. · 2007 [cited by applicant]
US 7229401B2 · Kindlein · 2007 [cited by applicant]
US 7387628B1 · Behl et al. · 2008 [cited by applicant]
US 7517346B2 · Sloan et al. · 2009 [cited by applicant]
US 7918795B2 · Grossman · 2011 [cited by applicant]
US 7963941B2 · Wilk · 2011 [cited by applicant]
US 8080009B2 · Lee et al. · 2011 [cited by applicant]
US 8157741B2 · Hirota · 2012 [cited by applicant]
US 8157745B2 · Schoot · 2012 [cited by applicant]
US 8206300B2 · Deckman et al. · 2012 [cited by applicant]
US 8216231B2 · Behl et al. · 2012 [cited by applicant]
US 8221321B2 · McMorrow et al. · 2012 [cited by applicant]
US 8262574B2 · Placek et al. · 2012 [cited by applicant]
US 8287485B2 · Kimura et al. · 2012 [cited by applicant]
US 8377041B2 · Frassica et al. · 2013 [cited by applicant]
US 8469893B2 · Chiang et al. · 2013 [cited by applicant]
US 8506485B2 · Deckman et al. · 2013 [cited by applicant]
US 8512330B2 · Epstein et al. · 2013 [cited by applicant]
US 8512333B2 · Epstein et al. · 2013 [cited by applicant]
US 8540634B2 · Bruce et al. · 2013 [cited by applicant]
US 8585598B2 · Razzaque et al. · 2013 [cited by applicant]
US 8622911B2 · Hossack et al. · 2014 [cited by applicant]
US 8663130B2 · Neubach et al. · 2014 [cited by applicant]
US 8718339B2 · Tonomura et al. · 2014 [cited by applicant]
US 8814796B2 · Martin et al. · 2014 [cited by applicant]
US 8992427B2 · Munrow et al. · 2015 [cited by applicant]
US 9089287B2 · Sliwa et al. · 2015 [cited by applicant]
US 9119649B2 · Van et al. · 2015 [cited by applicant]
US 9198707B2 · McKay et al. · 2015 [cited by applicant]
US 9198719B2 · Murdeshwar et al. · 2015 [cited by applicant]
US 9247925B2 · Havel et al. · 2016 [cited by applicant]
US 9439627B2 · Case et al. · 2016 [cited by applicant]
US 9510898B2 · Epstein et al. · 2016 [cited by applicant]
US 9516996B2 · Diolaiti et al. · 2016 [cited by applicant]
US 9517047B2 · Grossman · 2016 [cited by applicant]
US 10595819B2 · Deckman · 2020 [cited by examiner]
US 11612431B2 · Chen · 2023 [cited by applicant]
US 20010014805A1 · Burbank et al. · 2001 [cited by applicant]
US 20070208327A1 · Rosemberg et al. · 2007 [cited by applicant]
US 20080228081A1 · Becker et al. · 2008 [cited by applicant]
US 20090043295A1 · Arnal et al. · 2009 [cited by applicant]
US 20090093718A1 · Jibiki et al. · 2009 [cited by applicant]
US 20100160781A1 · Carter et al. · 2010 [cited by applicant]
US 20100262133A1 · Hoey et al. · 2010 [cited by applicant]
US 20100312117A1 · Fernandez · 2010 [cited by examiner]
US 20110098564A1 · Larson et al. · 2011 [cited by applicant]
US 20110208061A1 · Chang · 2011 [cited by applicant]
US 20120010479A1 · Eusemann et al. · 2012 [cited by applicant]
US 20120035474A1 · Deckman et al. · 2012 [cited by applicant]
US 20120165813A1 · Lee et al. · 2012 [cited by applicant]
US 20120209115A1 · Tonomura · 2012 [cited by applicant]
US 20120277737A1 · Curley · 2012 [cited by applicant]
US 20120316440A1 · Munrow et al. · 2012 [cited by applicant]
US 20130041259A1 · Harks et al. · 2013 [cited by applicant]
US 20130085497A1 · Chang · 2013 [cited by examiner]
US 20130281863A1 · Chiang et al. · 2013 [cited by applicant]
US 20130317366A1 · Hirayama et al. · 2013 [cited by applicant]
US 20140073911A1 · Munrow et al. · 2014 [cited by applicant]
US 20140180273A1 · Nair · 2014 [cited by applicant]
US 20140276081A1 · Tegels · 2014 [cited by applicant]
US 20150150497A1 · Goldchmit · 2015 [cited by applicant]
US 20150173592A1 · Leeflang et al. · 2015 [cited by applicant]
US 20150257779A1 · Sinelnikov et al. · 2015 [cited by applicant]
US 20150335344A1 · Aljuri · 2015 [cited by examiner]
US 20160051221A1 · Dickhans et al. · 2016 [cited by applicant]
US 20160151041A1 · Lee et al. · 2016 [cited by applicant]
US 20160249878A1 · Grossman · 2016 [cited by applicant]
US 20160278740A1 · Negrila et al. · 2016 [cited by applicant]
US 20160310042A1 · Kesten et al. · 2016 [cited by applicant]
CN 102238921A · 2011 [cited by applicant]
JP 2007244857A · 2007 [cited by applicant]
JP 2009136523A · 2009 [cited by applicant]
JP 2013500778A · 2013 [cited by applicant]
JP 2013527782A · 2013 [cited by applicant]
JP 2013529943A · 2013 [cited by applicant]
WO WO2009027890A1 · 2009 [cited by applicant]
WO WO2015087203A1 · 2015 [cited by applicant]
WO WO2018201158A1 · 2018 [cited by applicant]
WO WO2018204284A1 · 2018 [cited by applicant]
EP18794337.8 Extended European Search Report dated Feb. 8, 2021. [cited by applicant]
International Search Report and Written Opinion for PCT/US2018/30295 on Sep. 13, 2018. [cited by applicant]
U.S. Appl. No. 16/666,271 Notice of Allowance dated Nov. 30, 2022. [cited by applicant]
U.S. Appl. No. 16/666,271 Office Action dated Dec. 10, 2021. [cited by applicant]
U.S. Appl. No. 16/666,271 Office Action dated Jul. 1, 2022. [cited by applicant]